Analyst Price Targets — BIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 12:06 pm | — | RBC Capital | $390.00 | $346.66 | TheFly | Bio-Rad price target raised to $390 from $370 at RBC Capital |
| August 5, 2026 11:34 am | — | RBC Capital | $370.00 | $332.70 | TheFly | Bio-Rad price target raised to $370 from $320 at RBC Capital |
| May 25, 2026 9:06 am | — | Wells Fargo | $310.00 | $287.74 | TheFly | Bio-Rad price target raised to $310 from $290 at Wells Fargo |
| May 14, 2026 8:24 pm | — | RBC Capital | $320.00 | $246.27 | TheFly | Bio-Rad resumed with an Outperform at RBC Capital |
| May 1, 2026 10:27 am | — | Wells Fargo | $290.00 | $280.12 | TheFly | Bio-Rad price target lowered to $290 from $320 at Wells Fargo |
| February 16, 2026 12:43 pm | Brandon Couillard | Wells Fargo | $320.00 | $256.56 | TheFly | Bio-Rad price target lowered to $320 from $340 at Wells Fargo |
| February 13, 2026 2:33 pm | — | UBS | $335.00 | $259.64 | TheFly | Bio-Rad price target lowered to $335 from $350 at UBS |
| October 30, 2025 10:28 am | — | Wells Fargo | $340.00 | $319.47 | TheFly | Bio-Rad price target raised to $340 from $265 at Wells Fargo |
| October 1, 2024 5:34 am | Patrick Donnelly | Citigroup | $400.00 | $338.58 | StreetInsider | Citi Upgrades Bio-Rad Labs (BIO) to Buy |
| December 7, 2022 4:42 am | — | RBC Capital | $565.00 | $399.59 | Benzinga | RBC Capital Initiates Coverage On Bio-Rad Laboratories with Outperform Rating, Announces Price Target of $565 |
Latest News for BIO
HOLMDEL, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management and biometric authentication technologies, announced that its CEO Michael DePasquale will be available for virtual meetings at H.C.
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargo's 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM Eastern Time (12:45 PM Pacific Time). A live…
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
BIO-key's (BKYI)Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.